Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Observed Consensus correctly preserves the remaining-life denominator. Original Methods/Results show about 8.9 versus 18.5 remaining weeks after treatment at 124 weeks, with concurrent buffer controls and a historical control-AAV argument. This supports a real animal signal with delivery-control limits, not doubled total life or human efficacy. Original PMID38381405. Access: full_text_partial.
Provider summarizes older-donor keratinocyte clock reversal. Actual M/R identify an immortalized scalp-derived line, puromycin survivor selection and terminal healthy-animal selection for mouse methylation. These facts constrain selection and recipient interpretation; the human component is not an adult clinical intervention. Original PMID38381405. Access: full_text_partial.
Provider describes human-cell rejuvenation without erased identity, while its fuller wording notes no permanent loss. Actual M/R explicitly show temporary fibroblast identity suppression, sorting of intermediate states and later recovery. Retained final identity does not prove no intermediate dedifferentiation or universal safe control. Original PMID35390271. Access: full_text_partial.
Provider reports approximately thirty clock-years and collagen recovery. Actual Results retain those findings but show variable migration that did not correlate with clocks, multiple unresponsive clocks and no telomere-clock rejuvenation. This directly bounds clock-to-function surrogacy without discarding real partial cellular function. Original PMID35390271. Access: full_text_partial.
Provider correctly separates cell culture and grafts from systemic patients. Original Methods identify human donors and immunocompromised mouse recipients; actual force benefit is in mouse muscle, whereas human-cell graft benefit is assessed by mouse bioluminescence. No human strength or clinical-healthspan result is claimed. Original PMID32210226. Access: full_text_partial.
Provider gives TET-related regenerative benefit largely through reviews. Selected original Results confirm Tet1/Tet2/TDG dependence, but also show global Tet1 catalytic demethylation alone did not protect or regenerate. Actual vision improvement is retained while rejecting sufficiency of a younger methylation state alone. Original PMID33268865. Access: full_text_partial.
The provider emphasizes local retinal efficacy. Original Methods use blinded optomotor assessment and separate test samples, but clock-feature selection includes injury and OSK-response associations; original Results do not show the oldest visual-acuity benefit. Independent marker samples are useful but do not make the score a universal prospective clinical surrogate. Original PMID33268865. Access: full_text_partial.
Provider largely discusses rodent positives and does not resolve this requested original organism. Actual M/R establish Drosophila, adult expression without embryonic induction, temperature-matched controls, cyclic survival benefits and continuous-expression detriment. It is neither a mouse senolytic trial nor a human treatment, and its mortality modeling complicates a universal aging-rate reduction claim. Original PMID36287172. Access: full_text_partial.
Provider suggests omission of c-Myc reduces tumorigenesis, which may be valid in specific later systems. The examined original AAV abstract nevertheless reports full in vivo reprogramming without c-Myc, teratomas and vector integration. Omitting one oncogene is not a general safety certificate; full and controlled partial protocols remain distinct. Original PMID29985406. Access: abstract_metadata.
Provider retains aged-cell-targeted OSK survival and wound-healing positives. The original abstract reports no changed observed tumor incidence in its mouse setting. That is useful bounded feasibility evidence rather than proof of absent neoplasia across deliveries, humans or longer follow-up. Original PMID39259812. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.